WASHINGTON, Aug 21 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) (GSK.N: Quote, Profile, Research) has said it will add a boxed warning about possible heart risk to its attention deficit hyperactivity drug Dexedrine, according to a letter posted to the U.S. Food and Drug Administration’s Web site on Monday.
